Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study
Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Rita Assi(Lebanese American University), Naval Daver(The University of Texas MD Anderson Cancer Center), Christopher B. Benton(The University of Texas MD Anderson Cancer Center), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center), Philip A. Thompson(The University of Texas MD Anderson Cancer Center), Gautam Borthakur(The University of Texas MD Anderson Cancer Center), Yesid Alvarado(The University of Texas MD Anderson Cancer Center), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Marina Konopleva(The University of Texas MD Anderson Cancer Center), Koichi Takahashi(The University of Texas MD Anderson Cancer Center), Steven M. Kornblau(The University of Texas MD Anderson Cancer Center), Courtney D. DiNardo(The University of Texas MD Anderson Cancer Center), Zeev Estrov(The University of Texas MD Anderson Cancer Center), Wilmer Flores(The University of Texas MD Anderson Cancer Center), Sreyashi Basu(The University of Texas MD Anderson Cancer Center), James P. Allison(The University of Texas MD Anderson Cancer Center), Padmanee Sharma(The University of Texas MD Anderson Cancer Center), Sherry Pierce(The University of Texas MD Anderson Cancer Center), Allison Pike(The University of Texas MD Anderson Cancer Center), Jörge E. Cortes(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center)
Cited by 137Open Access